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A B S T R A C T
Background
Long-acting bronchodilators comprising long-acting beta2-agonists and the anticholinergic agent tiotropium are commonly used for
managingpersistent symptomsof chronic obstructive pulmonary disease.Combining these treatments, which have differentmechanisms
of action, may be more effective than the individual components. However, the benefits and risks of combining tiotropium and long-
acting beta2-agonists for the treatment of chronic obstructive pulmonary (COPD) disease are unclear.
Objectives
To assess the relative effects of treatment with tiotropium in addition to long-acting beta2-agonist compared to tiotropium or long-
acting beta2-agonist alone in patients with chronic obstructive pulmonary disease.
Search methods
We searched the Cochrane Airways Group Specialised Register of trials and clinicaltrials.gov up to January 2012.
Selection criteria
We included parallel group, randomised controlled trials of three months or longer comparing treatment with tiotropium in addition
to long-acting beta2-agonist against tiotropium or long-acting beta2-agonist alone for patients with chronic obstructive pulmonary
disease.
Data collection and analysis
Two review authors independently assessed trials for inclusion and then extracted data on trial quality and the outcome results. We
contacted study authors for additional information. We collected information on adverse effects from the trials.
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Main results
Five trials were included in this review, mostly recruiting participants with moderate or severe chronic obstructive pulmonary disease.
All of them compared tiotropium in addition to long-acting beta2-agonist to tiotropium alone, but only one trial additionally compared
a combination of the two types of bronchodilator with long-acting beta2-agonist (formoterol) alone. Two studies used the long-acting
beta2-agonist indacaterol, two used formoterol and one used salmeterol.
Compared to tiotropium alone (3263 patients), treatment with tiotropium plus long-acting beta2-agonist resulted in a slightly larger
improvement in the mean health-related quality of life (St George’s Respiratory Questionnaire (SGRQ) MD -1.61; 95% CI -2.93 to
-0.29). In the control arm, tiotropium alone, the SGRQ improved by falling 4.5 units from baseline and with both treatments the
improvement was a fall of 6.1 units from baseline (on average). High withdrawal rates in the trials increased the uncertainty in this
result, and the GRADE assessment for this outcome was therefore moderate. There were no significant differences in the other primary
outcomes (hospital admission or mortality).
The secondary outcome of pre-bronchodilator FEV1 showed a small mean increase with the addition of long-acting beta2-agonist
(MD 0.07 L; 95% CI 0.05 to 0.09) over the control arm, which showed a change from baseline ranging from 0.03 L to 0.13 L on
tiotropium alone. None of the other secondary outcomes (exacerbations, symptom scores, serious adverse events, and withdrawals)
showed any statistically significant differences between the groups. There were wide confidence intervals around these outcomes and
moderate heterogeneity for both exacerbations and withdrawals.
The results from the one trial comparing the combination of tiotropium and long-acting beta2-agonist to long-acting beta2-agonist
alone (417 participants) were insufficient to draw firm conclusions for this comparison.
Authors’ conclusions
The results from this review indicate a small mean improvement in health-related quality of life for patients on a combination of
tiotropium and long-acting beta2-agonist compared to tiotropium alone, but it is not clear how clinically important this mean difference
may be. Hospital admission and mortality have not been shown to be altered by adding long-acting beta2-agonists to tiotropium. There
were not enough data to determine the relative efficacy and safety of tiotropium plus long-acting beta2-agonist compared to long-acting
beta2-agonist alone. There were insufficient data to make comparisons between the different long-acting beta2-agonists when used in
addition to tiotropium.
P L A I N L A N G U A G E S U M M A R Y
Is it better to take a combination of tiotropium and long-acting beta2-agonists than either inhaler alone for the treatment of
COPD?
Chronic obstructive pulmonary disease (COPD) is a lung disease which includes the conditions chronic bronchitis and emphysema.
The symptoms include breathlessness and a chronic cough. COPD is an irreversible disease that is usually brought on by airway irritants,
such as smoking or inhaled dust.
Long-acting beta2-agonists and tiotropium are two types of inhaled medications that help widen the airways (bronchodilators) for
up to 12 to 24 hours. These bronchodilators are commonly used to manage persistent symptoms of COPD. They can be used in
combination or on their own. These bronchodilators work in different ways and therefore might be more beneficial if used together.
The purpose of this review was to determine the benefits and risks of using a combination of both types of bronchodilator compared
to the individual bronchodilators.
We found five studies involving 3263 patients comparing the long-term efficacy and side effects of combining tiotropium with a long-
acting beta2-agonist. The combination of tiotropium plus long-acting beta2-agonist resulted, on average, in a slightly better quality
of life and lung function for the patients compared to using only tiotropium, but did not show a difference in hospital admissions
or mortality. There were not enough data to determine the risks and benefits of tiotropium plus long-acting beta2-agonist treatment
compared to long-acting beta2-agonist alone.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
LABA plus tiotropium versus tiotropium for chronic obstructive pulmonary disease
Patient or population: chronic obstructive pulmonary disease
Settings:
Intervention: LABA plus tiotropium versus tiotropium
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Tiotropium LABA plus tiotropium
Change in quality of life
St George’s Respira-
tory Questionaire (SGRQ)
. Scale from: 0 to 100.
Follow-up: 6 to 12
months
The mean change in qual-
ity of life in the control
group was
-4.5 units1
The mean change in qual-
ity of life in the interven-
tion group was
-6.3 units1
(-7.43 to -4.79)
MD -1.61
(-2.93 to -0.29)
732
(2 studies)
⊕⊕⊕©
moderate2
The mean treatment ef-
fect was statistically sig-
nificant but it was smaller
than what is regarded as
a clinically important dif-
ference
Exacerbations leading to
hospital admission
Number of patients ex-
periencing one or more
events
Follow-up: 6 to 12
months
88 per 1000 93 per 1000
(57 to 148)
OR 1.07
(0.63 to 1.81)
732
(2 studies)
⊕⊕©©
low2,3
Hospital admission (all
cause)
Number of patients ex-
periencing one or more
events
Follow-up: 6 to 12
months
119 per 1000 120 per 1000
(79 to 179)
OR 1.01
(0.63 to 1.61)
732
(2 studies)
⊕⊕©©
low2,3
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Mortality (all cause)
Number of patients
Follow-up: 3 to 12
months
4 per 1000 6 per 1000
(2 to 16)
OR 1.56
(0.56 to 4.33)
3263
(5 studies)
⊕⊕©©
low4
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 The control group risk is based on Aaron 2007.
2 One study was a year long with high and unbalanced dropouts.
3 Wide confidence interval and few participants and events.
4 There were two trials with no deaths and few deaths in the remaining three trials, leading to a wide confidence interval. Mortality was
largely unknown in those who discontinued treatment.
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B A C K G R O U N D
Description of the condition
Chronic Obstructive Pulmonary Disease (COPD) is a respiratory
disease characterised by chronic and progressive breathlessness,
cough, sputum production, and airflow obstruction, which leads
to restricted activity and poor quality of life (GOLD). The World
Health Organization (WHO) has estimated that COPD is the
fourth or fifth most common single cause of death worldwide and
the treatment and management costs present a significant burden
to public health. In the UK the annual cost of COPD to the Na-
tional Health Service (NHS) is estimated to be £1.3 million per
100,000 people (NICE 2011). Furthermore, because of the slow
onset and the under-recognition of the disease, it is heavily under-
diagnosed (GOLD). COPD comprises a combination of bronchi-
tis and emphysema and involves chronic inflammation and struc-
tural changes in the lung. Cigarette smoking is the most impor-
tant risk factor, however air pollution and occupational dust and
chemicals are also recognised risk factors. COPD is a progressive
disease leading to decreased lung function over time, even with the
best available care. There is currently no cure for COPD, though
it is both a preventable and treatable disease. As yet, apart from
smoking cessation and non-pharmacological treatments such as
long term oxygen therapy in hypoxic patients, no intervention has
been shown to reducemortality (GOLD).Management of the dis-
ease is multi-faceted and includes interventions for smoking cessa-
tion (van der Meer 2001), pharmacological treatments (GOLD),
education (Effing 2007), and pulmonary rehabilitation (Lacasse
2006). Pharmacological therapy is aimed at relieving symptoms,
improving exercise tolerance and quality of life, slowing decline
and even improving lung function, or preventing and treating ex-
acerbations. COPD exacerbations impair patients’ quality of life
(GOLD). Furthermore, a large part of the economic burden of
COPD is attributed to the cost of managing exacerbations, par-
ticularly those resulting in use of acute care services or hospital-
isations (Hutchinson 2010). In the UK, one in eight emergency
admissions to hospital is for COPD, which makes it the second
largest cause of emergency admissions and one of the most costly
conditions treated by the NHS (NICE 2011). Appropriate phar-
macological management of the disease is therefore important to
try to reduce and prevent exacerbations.
Description of the intervention
COPD pharmacological management tends to begin with one
treatment and additional therapies are introduced, as necessary,
to control symptoms (GOLD). The first step is often a short-act-
ing bronchodilator for control of breathlessness when needed, ei-
ther a short-acting beta2-agonist or the short-acting anticholiner-
gic agent ipratropium. For persistent or worsening breathlessness
associated with lung function decline, long-acting bronchodila-
torsmay be introduced (GOLD). Long-acting bronchodilators in-
clude long-acting beta2-agonists (LABA), such as salmeterol or for-
moterol; new ultra long-acting beta2-agonist, such as indacaterol;
and the long-acting anticholinergic agent tiotropium. For symp-
tomatic patients with severe or very severe COPD (FEV1 < 50%
predicted) and repeated exacerbations, GOLD recommends the
addition of inhaled corticosteroids (ICS) to bronchodilator treat-
ment.
How the intervention might work
Tiotropium
Tiotropium is an anticholinergic agent which blocks the action
of the neurotransmitter acetylcholine. It has an antagonistic ef-
fect onmuscarinic acetylcholine receptors. Tiotropium has similar
affinity for the five different subtypes of muscarinic receptors (M1
to M5), however airway smooth muscle expresses only the M2
and M3 subtypes (Proskocil 2005). Activation of the M3 recep-
tor stimulates a number of intracellular signalling cascades lead-
ing to changes in intracellular Ca2+ homeostasis and contraction.
Tiotropium dissociates slowly from M3 receptors giving a bron-
chodilator effect lasting over 24 hours, but dissociates rapidly from
M2 receptors, which appear to be feedback inhibitory receptors
(Barr 2005).
Tiotropium has gained widespread acceptance as a once daily
maintenance therapy in stable COPD (Barr 2005; GOLD) for
its effects on symptoms and exacerbations. In an early Cochrane
review (Barr 2005) tiotropium was shown to reduce the primary
endpoint of participants with COPD exacerbations compared to
placebo (odds ratio (OR) 0.75; 95% CI 0.66 to 0.85). Within the
same review, tiotropium was also associated with a significant ben-
efit over placebo in breathlessness, quality of life, and a reduction
in participants with exacerbations that required hospitalisation.
Similar effects on symptoms and exacerbations were confirmed in
a more recent, large randomised controlled trial of almost 6000
patients who were followed for over four years (Tashkin 2008).
There was, however, no significant effect of tiotropium on lung
function decline in this longer study. Anticholinergic side effects
that may occur with tiotropium include dry mouth, constipation
and tachycardia (Tashkin 2008). There has been concern expressed
about cardiovascular adverse events on tiotropium (Singh 2009),
but this was not shown in meta-analysis including the recent UP-
LIFT study (Celli 2010).
Long-acting beta2-agonists
Inhaled beta2-agonists activate beta2-receptors in the smoothmus-
cle of the airway leading to a cascade of reactions that result in bron-
chodilation. Beta2-agonists may also act through other mecha-
nisms such as respiratory muscle function ormucociliary clearance
5Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive
pulmonary disease (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
because patients have shown improvements in symptoms whilst
showing no improvement in lung function tests. Beta2-agonists
are particularly useful bronchodilators because they reverse bron-
choconstriction regardless of the initial cause. The commonly used
long-acting beta2-agonists salmeterol and formoterol and the ultra
long-acting beta2-agonist indacaterol all have a higher selectivity
for beta2-receptors than beta1-receptors (Moen 2010; Wallukat
2002). Beta2-receptors are the predominant adrenergic receptors
in bronchial smooth muscle and beta1-receptors are the predomi-
nant receptors in the heart, although 10% to 50%of the total beta-
receptors in the heart are comprised of beta2-receptors. The pres-
ence of beta2-receptors in the heart raises the possibility that even
highly selective beta2-agonists may have cardiac effects. The dura-
tion of action for salmeterol and formoterol is approximately 12
hours, and they are therefore usually taken twice daily. Indacaterol
has a duration of action of 24 hours and can, therefore, be taken
once daily. The mechanism for activating beta2-receptors differs
between these long-acting beta2-agonists. Formoterol is taken up
into a membrane depot from where it gradually leaks out to in-
teract with the receptor, whilst salmeterol binds near the recep-
tor, allowing it to remain at the receptor site continually binding
and releasing (Johnson 1998). Indacaterol has a higher affinity to
lipid domains within the membrane than salmeterol, which may
potentially explain its prolonged duration of action (Beier 2011).
Independent of long-acting beta2-agonist (LABA) type, stimu-
lation of the beta2-receptors leads to changes in intracellular
Ca2+ homeostasis and bronchodilation (Tanaka 2005). As with
tiotropium, LABAs are used as ’symptom controllers’ in stable
COPD. A prior Cochrane review found that salmeterol improves
lung function compared to placebo (Appleton 2006). A more
recent, large (3045 patients), long-term (three-year) randomised
control trial also compared salmeterol to placebo (TORCH)
(Calverley 2007). In this trial salmeterol use was associated with
an increase in lung function and a significant reduction in the
annual rate of moderate or severe exacerbations compared with
placebo (rate ratio 0.85, P < 0.001). A systematic review, which
included the TORCH study and another 13 trials looking at sal-
meterol or formoterol (6453 participants), showed that treatment
with a LABA reduced the rate of exacerbations and improved lung
function and quality of life compared to placebo, but had no sig-
nificant effect on mortality (Rodrigo 2008). There have also been
a few studies on indacaterol showing improvements in lung func-
tion, quality of life and exacerbations compared to placebo (Moen
2010). Possible side effects of LABAs include cardiac effects such
as arrhythmia and palpitations, and muscle tremors, head ache,
cough, and dry mouth (Beeh 2009; Berger 2008).
Why it is important to do this review
Both tiotropium and long-acting beta2-agonists are recommended
for treatment of stable COPD (GOLD). However, patients whose
COPD is not adequately managed by either LABA or tiotropium
treatment alone could potentially benefit from treatment with a
combination of the two. It has been suggested that combination
therapies directed at both adrenergic and muscarinic receptors
could provide greater, and potentially additive, bronchodilation
compared with a beta2-agonist or a muscarinic antagonist alone
(Proskocil 2005). A number of trials have been published look-
ing at the effect of adding tiotropium to LABA for treatment of
COPD, and the clinical evidence to date suggests there may be
benefits in combining the treatments without increasing side ef-
fects (Cazzola 2010). This review is necessary to specify and quan-
tify the potential benefits from the combination treatment with
LABA and tiotropium compared to the individual components
alone.
This review will form part of a suite of reviews on the various
combinations of tiotropium, long-acting beta2-agonists and in-
haled corticosteroids for the treatment of COPD. These reviews
will ultimately be summarised in an overview. The first two of
these reviews compared a combination of inhaled corticosteroids
and long-acting beta2-agonists with tiotropium (Welsh 2010) and
triple therapy (inhaled corticosteroids, long-acting beta2-agonist
and tiotropium) with either tiotropium alone or inhaled corticos-
teroid (ICS) and LABA combination therapy (Karner 2011). Fur-
ther reviews are in preparation comparing alternate permutations
of these three drugs.
O B J E C T I V E S
To compare the relative effects on markers of quality of life, exac-
erbations, symptoms, lung function and serious adverse events in
patients with chronic obstructive pulmonary disease randomised
to the following therapies:
• long-acting beta2-agonists and tiotropium versus long-
acting beta2-agonists alone; or
• long-acting beta2-agonists and tiotropium versus
tiotropium alone.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised trials (RCTs) with a parallel group
design of at least 12 weeks duration. We did not exclude studies
on the basis of blinding.
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Types of participants
We included populations with a diagnosis of chronic obstructive
pulmonary disease. We only included studies where an external
set of criteria had been used to screen participants for this con-
dition (for example the Global initiative for chronic Obstructive
LungDisease (GOLD), American Thoracic Society (ATS), British
Thoracic Society (BTS), Thoracic Society of Australia and New
Zealand (TSANZ)).
Types of interventions
We included participants who were randomised to receive inhaled
long-acting beta2-agonist in addition to tiotropium bromide com-
pared to those on either inhaled tiotropium bromide alone or in-
haled long-acting beta2-agonist alone. We allowed any formula-
tion of long-acting beta2-agonists and tiotropium bromide. Par-
ticipants were allowed inhaled steroids and other co-medications
provided they were not part of the randomised treatment.
Types of outcome measures
Primary outcomes
1. Quality of life (measured with a validated scale for COPD,
e.g. St George’s Respiratory Questionnaire, Chronic Respiratory
Disease Questionnaire)
2. Hospital admissions; all cause and due to exacerbations
3. Mortality; all-cause
4. Disease specific mortality, if independently adjudicated
Secondary outcomes
1. Exacerbations; requiring short burst oral corticosteroids or
antibiotics, or both
2. Forced expiratory volume in one second (FEV1)
3. Symptoms
4. All-cause non-fatal serious adverse events
5. Disease specific serious adverse events, if independently
adjudicated
6. Withdrawals
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group Spe-
cialised Register of trials (CAGR), which is derived from system-
atic searches of bibliographic databases including the Cochrane
Central Register of Controlled Trials (CENTRAL), MEDLINE,
EMBASE,CINAHL, AMED, and PsycINFO, and handsearching
of respiratory journals and meeting abstracts (please see Appendix
1 for further details). All records in the CAGR coded as ’COPD’
were searched in January 2012 using the following terms:
(tiotropium or spiriva) AND (*formoterol or salmeterol or bam-
buterol or indacaterol or clenbuterol or Serevent or Foradil or Oxis
or (beta* and agonist*))
Clinicaltrials.govwas also searched in September 2011. The search
terms are in Appendix 2. All databases were searched from their
inception to the present and there was no restriction on language
of publication.
Searching other resources
We searched the following manufacturer websites in September
2011: Boehringer Ingelheim (Spiriva, Spiriva Respimat); Pfizer
(Spiriva); Novartis (indacaterol, formoterol); GlaxoSmithKline
(salmeterol); AstraZeneca (formoterol).We reviewed reference lists
of all primary studies and review articles for additional references.
Data collection and analysis
Selection of studies
Two review authors screened the titles and abstracts of citations
retrieved through literature searches and obtained those deemed
to be potentially relevant. We assigned each reference to a study
identifier and independently assessed them against the inclusion
criteria of this review.
Data extraction and management
We extracted information from each study for the following char-
acteristics.
1. Design (design, total study duration and run-in, number of
study centres and location, withdrawals, date of study).
2. Participants (N, mean age, age range, gender, COPD
severity, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, exclusion criteria).
3. Interventions (run-in, intervention treatment and inhaler
type, control treatment and inhaler type).
4. Outcomes (primary and secondary outcomes specified and
collected, time points reported).
Two authors extracted data from the studies into data collection
forms. We discussed and resolved any discrepancies in the data, or
consulted a third party where necessary. We transferred data from
the data collection forms into Review Manager 5.
Assessment of risk of bias in included studies
We assessed the risk of bias according to recommendations out-
lined in the Cochrane Handbook for Systematic reviews of Interven-
tions (Higgins 2008) for the following items.
1. Allocation sequence generation.
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2. Concealment of allocation.
3. Blinding of participants and investigators.
4. Incomplete outcome data.
5. Selective outcome reporting.
We noted other sources of bias. We graded each potential source
of bias as low, high or unclear risk of bias.
Measures of treatment effect
Dichotomous data
We analysed dichotomous data variables (such as mortality and
withdrawals) using odds ratios (OR). If count data were not avail-
able as the number of participants experiencing an event, we anal-
ysed the data as continuous, time-to-event or rate ratios, depend-
ing on how they were reported. This includes the outcomes: hos-
pital admissions, exacerbations, and serious adverse events.
Continuous data
We analysed continuous outcome data (such as FEV1 and quality
of life) as fixed-effectmodelmean differences (MD)when the same
scale was used, and standardised mean differences when different
scales were employed in different studies. Mean difference based
on the change from baseline was preferred over mean difference
based on absolute values.
If data were not available for the same time point in all studies,
we used the closest time points. Alternatively, end of study was
used as a time of analysis for all studies. We used intention-to-
treat (ITT) analysis onoutcomes fromall randomised participants,
where possible, for primary analyses.
Unit of analysis issues
We analysed dichotomous data using participants as the unit of
analysis (rather than events) to avoid counting the same participant
more than once.
Dealing with missing data
We contacted investigators or study sponsors in order to verify key
study characteristics and obtain missing numerical outcome data,
where possible. We also considered the impact of the unknown
status of participants who withdrew from the trials as part of the
sensitivity analysis.
Assessment of heterogeneity
We assessed the amount of statistical variation between the study
results with the I2 statistic measurement.
Assessment of reporting biases
We minimised reporting bias from non-publication of studies or
selective outcome reporting by using a broad search strategy, con-
tacting study authors directly and checking references of included
studies. If we had found sufficient numbers of trials, we planned
to visually inspect funnel plots.
Data synthesis
We combined dichotomous data using Mantel-Haenzsel odds ra-
tios with 95% confidence intervals, with a fixed-effect model.
Where events were rare, we employed the Peto odds ratio (OR)
(since this does not require a continuity correction for zero cells).
Where treatment effects were reported as a mean difference with
95% confidence interval or exact P value, we calculated the stan-
dard error, entered it with the mean difference (MD) and com-
bined the results using a fixed effect Generic Inverse Variance
(GIV) model in Review Manager 5.
Rate ratios and hazard ratios were combined using a fixed-effect
GIV model.
Numbers needed to treat would have been calculated from the
pooled odds ratio and its confidence interval (CI), and applied to
appropriate levels of baseline risk.
We presented the findings of our primary outcomes in a summary
of findings table using GradePro software and recommendations
in the Handbook for Systematic Reviews of Interventions (Higgins
2008).
Subgroup analysis and investigation of heterogeneity
Studies were subgrouped, where possible, according to:
1. type of long-acting beta-agonist;
2. severity of disease at baseline; and
3. tiotropium formulation.
Sensitivity analysis
We assessed the sensitivity of our primary outcomes to degree of
bias by comparing the overall results with those exclusively from
trials assessed as being at low risk of bias. We also compared the
results from the fixed-effect models with results from random-
effects models.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
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Results of the search
The database search identified 172 references in September 2011
and an additional five references in January 2012. Of these we
identified 27 as potentially relevant, which we obtained in full
text for further assessment. Fifteen of these were eligible and be-
longed to five studies (Aaron 2007;Mahler 2010a; Mahler 2010b;
Tashkin 2009; Vogelmeier 2008) (see Characteristics of included
studies). Searching the manufacturers’ websites we found study
reports for three of the included studies (Mahler 2010a; Mahler
2010b; Vogelmeier 2008). Searching clinicaltrials.gov in Septem-
ber 2011 did not generate any additional eligible trials. For the
study flow diagram see Figure 1.
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Figure 1. Study flow diagram.
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Included studies
Study design
The longest study was Aaron 2007 with a duration of one year,
then Vogelmeier 2008 with 24 weeks and Mahler 2010a, Mahler
2010b and Tashkin 2009 with 12 weeks of treatment. They were
all multi-centre studies. The Aaron 2007 study was conducted at
27 Canadian medical centres, Tashkin 2009 in 35 centres across
the United States, and three studies were conducted in a large
number of study centre in several different countries (Mahler
2010a; Mahler 2010b; Vogelmeier 2008).
Sample size
There were 3473 participants randomised to the relevant treat-
ment arms in the included studies: LABA + tiotropium (1621),
tiotropium (1642), and LABA (210).
Participants
The mean age of participants varied from 63 to 68 years. The
gender distribution varied from 54% to 79% males. All studies
included participants with moderate to severe COPD, although
Aaron 2007 and Vogelmeier 2008 also included patients with
very severe COPD (FEV1 less than 30% predicted) according to
GOLD guideline definitions of COPD. The mean baseline lung
function varied between 38% and 52% predicted across the stud-
ies.
Interventions
All included studies used 18 µg of tiotropium (Handihaler), one
inhalation daily. In Aaron 2007 the LABA used was salmeterol
25 µg/puff, two puffs twice daily using a pressurized metered-
dose inhaler and a spacer device. Both Mahler 2010a and Mahler
2010b used indacaterol single-dose dry powder inhaler (SDDPI)
at 150 µg once daily. Tashkin 2009 and Vogelmeier 2008 both
used formoterol. In Tashkin 2009 the dose used was 12 µg twice
daily (Foradil Aerolizer) and inVogelmeier 2008 the concentration
was 10 µg twice daily (multi-dose dry powder inhaler).
Permitted co-treatment
In all five studies participants were allowed to use inhaled salbuta-
mol, when necessary, to relieve symptoms. Mahler 2010a, Mahler
2010b, Tashkin 2009 and Vogelmeier 2008 permitted continued
use of regimens of inhaled corticosteroid that were stable prior to
entry throughout the study. In Aaron 2007 respiratory medica-
tions such as oxygen, antileukotrienes, and methylxanthines were
continued in all patient groups.
Outcomes
The primary outcome for Aaron 2007 was the proportion of pa-
tients suffering one or more COPD exacerbations. The primary
outcome for Vogelmeier 2008 was FEV1measured two hours post-
dose at the end of the study. In Tashkin 2009 the primary outcome
was also post-dose FEV1, but the normalised area under the curve
for FEV1 measured from zero to four hours post-morning dose at
the last visit.
Funding
The Aaron 2007 study was funded by the Canadian Institutes of
Health Research and the Ontario Thoracic Society. The Tashkin
2009 study was funded by Schering-Plough (markets formoterol)
and Mahler 2010a, Mahler 2010b and Vogelmeier 2008 by No-
vartis (markets formoterol and indacaterol).
Excluded studies
Eleven studies failed to meet the eligibility criteria for the review
(see Characteristics of excluded studies). Seven of these compared
tiotropiumalonewith a long-acting beta2 -agonist but hadno treat-
ment armwith a combination of the two (Bateman 2001; Brusasco
2003; Di Marco 2003; Fujimoto 2007; Gross 2003; Meyer 2008;
ten Hacken 2007). Six studies were of crossover design (Gross
2003; Jones 2010; Meyer 2008; ten Hacken 2007; van Noord
2003; van Noord 2005) and seven had a treatment period shorter
than 12 weeks (Fujimoto 2007; Gross 2003; Meyer 2008; New
2009; ten Hacken 2007; van Noord 2003; van Noord 2005).
Risk of bias in included studies
An assessment of the risk of bias is presented in the Characteristics
of included studies table, and an overview of the findings is shown
in (Figure 2).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All three studies reported adequate sequence generation, through
a computer generated system, and allocation concealment. Infor-
mation from Vogelmeier 2008 was kindly supplied on request. In
Aaron 2007 and Vogelmeier 2008 randomisation data were kept
strictly confidential until the time of unblinding, and was not ac-
cessible by anyone involved in the study before or after randomi-
sation. In Tashkin 2009 the randomisation code was labelled on
the medication kit.
Blinding
The blinding in Aaron 2007 was adequate. In Aaron 2007 both re-
search staff and patients were blinded to the treatment assignment
until the end of the study. The different inhalers were identical
and they were enclosed in tamper-proof blinding devices. Clini-
cal data for suspected exacerbations were reviewed by a blinded
committee and the statistician who performed the analysis was
initially blinded to patient group assignments. The Vogelmeier
2008 study was partially blinded with tiotropium being admin-
istered open-label, but double-blind for the long-acting beta2-ag-
onist treatment. The risk of performance bias was therefore high
for the comparison LABA + tiotropium versus LABA, and low for
LABA + tiotropium versus tiotropium. The risk of detection bias
was also low as outcome assessors and data analysts were blinded
to patient group assignments. Information from Vogelmeier 2008
was kindly supplied on request. Tashkin 2009 did not fully de-
scribe in the study report who was blinded.
Incomplete outcome data
Aaron 2007 suffered from high withdrawal rates in the different
study groups (74 patients (47%) withdrew from the tiotropium +
placebo group and 64 patients (43%) on LABA + tiotropium). For
most patients, data were recorded throughout the one-year trial
period regardless of whether patients discontinued treatment with
study medications. The rates of patients who stopped therapy and
did not complete the trial were 30 patients (19%) on tiotropium
+ placebo and 20 patients (14%) on LABA + tiotropium. Mor-
tality data were obtained for all participants with the exception
of two out of 148 participants (1.4%) on LABA + tiotropium
and four out of 156 participants (2.6%) on tiotropium + placebo,
who withdrew and declined further study. In Tashkin 2009 the
number of withdrawals was also uneven but was relatively low
(LABA + tiotropium (14.5%), and tiotropium + placebo (6.1%)).
In the other three studies the number of withdrawals in the dif-
ferent groups were relatively low and even (Mahler 2010a: LABA
+ tiotropium (6.8%) and tiotropium + placebo (6.2%); Mahler
2010b: LABA + tiotropium (5.1%) and tiotropium + placebo
(6.5%); Vogelmeier 2008: LABA + tiotropium (12%), LABA
(12%) and tiotropium + placebo (13%)).
Selective reporting
All the included studies adequately reported outcome data for the
primary and secondary outcomes that they had pre-specified in
the study records, but we did not compare reported outcomes to
the trial protocols.
Effects of interventions
See: Summary of findings for the main comparison LABA plus
tiotropium versus tiotropium for chronic obstructive pulmonary
disease
LABA plus tiotropium versus tiotropium
Weplanned to analyse the data using subgroups for disease severity,
type of long-acting beta2-agonist, and tiotropium formulation.
We subgrouped the data in the forest plots according to type of
long-acting beta2-agonist. However, these need to be interpreted
with caution because of the small number of trials and the many
significant differences between them, including length of study.
Primary outcome: quality of life
Two studies (729 participants) looked at changes in quality of life
using the St George’s Respiratory Questionnaire (SGRQ); Aaron
2007 added salmeterol to tiotropium and Vogelmeier 2008 added
formoterol to tiotropium. A decrease in SGRQ score denotes an
improvement in quality of life and a difference of at least four
units is regarded as clinically significant (SGRQ-C manual 2008).
Aaron 2007 showed an improvement in quality of life in the con-
trol arm, tiotropium alone, of -4.5 units after one year. The pooled
result of the treatment difference between LABA + tiotropium and
tiotropium alone showed that the combination treatment led to -
6.1 unit improvement in quality of life. This difference was sig-
nificantly larger (statistically) than with tiotropium alone (MD -
1.61; 95% CI -2.93 to -0.29), see Figure 3. The confidence inter-
val of this mean difference excludes the minimal clinically impor-
tant difference of four units but there is additional uncertainty in
relation to the quality of life in those patients who withdrew from
the study.
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Figure 3. Forest plot of comparison: 1 LABA plus tiotropium versus tiotropium, outcome: 1.1 Change in
quality of life.
Primary outcome: hospital admissions
Aaron 2007 and Vogelmeier 2008 (729 participants) also reported
the number of patientswhowere admitted tohospital for any cause
and due to exacerbations. Data for Aaron 2007 and Vogelmeier
2008 were kindly supplied on request. The number of hospitalised
patients were similar and there was no statistically significant dif-
ference between the treatment groups for hospitalisations for any
cause (OR 1.01; 95% CI 0.63 to 1.61) or due to exacerbation
(OR 1.07; 95% CI 0.63 to 1.81). There was a wide confidence
interval for the result as the total number of participants with an
event was low, and there was additional uncertainty arising from
the potential additional admissions that were not known in the
patients who withdrew. See Figure 4 and Figure 5 respectively.
Figure 4. Forest plot of comparison: 1 LABA plus tiotropium versus tiotropium, outcome: 1.2 Hospital
admission (all cause).
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Figure 5. Forest plot of comparison: 1 LABA plus tiotropium versus tiotropium, outcome: 1.3 Hospital
admission (exacerbation).
Primary outcome: mortality (all causes)
All five studies (3263 participants) reported mortality for for-
moterol, salmeterol and indacaterol, however, there were no deaths
during the study periods in Tashkin 2009 and Vogelmeier 2008.
In the remaining three studies there was no statistically significant
difference between the treatment groups as the number of events
was low, leading to wide confidence intervals for the difference be-
tween the groups (PetoOR1.56; 95%CI 0.56 to 4.33), see Figure
6. Moreover, there were considerably more participants who dis-
continued treatment than the numbers who died, adding further
uncertainty to the true impact on mortality.
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Figure 6. Forest plot of comparison: 1 LABA plus tiotropium versus tiotropium, outcome: 1.4 Mortality (all
cause).
Secondary outcome: exacerbations
Three studies (987 participants), on formoterol and salmeterol, re-
ported the number of patients suffering one or more exacerbation
during the study period (Aaron 2007; Tashkin 2009; Vogelmeier
2008). Aaron 2007 defined exacerbations as a sustained worsening
of the patient’s respiratory condition, from the stable state and be-
yond normal day-to-day variations, necessitating a change in reg-
ular medication in a patient with underlying COPD. Vogelmeier
2008 reported the number of patients suffering COPD exacerba-
tions who required additional therapy, defined as COPD-related
adverse events (AEs) requiring additional therapy, where COPD-
related AEs were defined as AEs coding to the preferred terms:
COPD, COPD exacerbated, cough, any term containing ’dysp-
noea’, lower respiratory tract infection, chronic bronchitis, bron-
chospasm, bronchial obstruction and respiratory failure; and ad-
ditional therapy was any COPD therapy reported as being used
to treat a COPD exacerbation, other than rescue bronchodilator.
In Tashkin 2009 the definition of exacerbation was not described,
but it was stated that most patients who needed treatment for
their exacerbations received antibiotics alone or a course of antibi-
otics and systemic steroids. The baseline risk also varied greatly
between the studies. In the one-year study (Aaron 2007) 62.8% of
patients on tiotropium alone experienced one or more exacerba-
tions, whereas in Tashkin 2009 and Vogelmeier 2008 the number
was 10.7% and 10.4%, respectively. There was also substantial
heterogeneity between the studies (I2 = 55%) and the exacerba-
tion status of the patients who withdrew from each study was un-
known. In Tashkin 2009 there were more patients experiencing
exacerbations in the LABA + tiotropium group (OR 1.70; 95%
CI 0.82 to 3.52); Vogelmeier 2008 showed the opposite result
(OR 0.58; 95% CI 0.28 to 1.17); and in Aaron 2007 there was
almost no difference between the groups (OR 1.09; 95% CI 0.68
to 1.75). In a sensitivity analysis Aaron 2007 reported a similar
result when assuming that all patients who were lost to follow up
had an exacerbation (OR 0.87; 95% CI 0.52 to 1.45). We did not
pool the results for this outcome due to the clinical heterogeneity
between the studies.
Secondary outcome: lung function (pre-dose FEV1)
All five studies (3263 participants) looked at lung function. Four
of the studies looked at different measures of post-bronchodilator
FEV1 as their primary outcome, but all five also reported pre-bron-
chodilator FEV1 values. The improvement in pre-bronchodila-
tor FEV1 at the end of the study showed a statistically signifi-
cant increase in the LABA + tiotropium group compared to the
tiotropium group (MD 0.07 L; 95% CI 0.05 to 0.09). The im-
provement in FEV1 in the control arm, tiotropium alone, after
six months of treatment was 0.13 L in Vogelmeier 2008 and 0.03
16Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive
pulmonary disease (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
L after one year in Aaron 2007. Data for both Aaron 2007 and
Vogelmeier 2008 were kindly supplied on request.
Secondary outcome: symptom score
Both Tashkin 2009 and Vogelmeier 2008 looked at changes in
symptom scores. However, we were not able to obtain standard
deviations for the data from Tashkin 2009. Vogelmeier 2008 used
a total daily symptom score which was the sum of the scores
for breathlessness, cough, wheeze, amount and colour of sputum.
Eachwere scored on a scale from zero to three where zerowas equal
to no symptoms. Vogelmeier 2008 kindly supplied data on request
which showed a large uncertainty and no statistically significant
difference between the treatment groups in total symptom score
(MD 0.21; 95% CI -0.30 to 0.72).
Secondary outcome: serious adverse events (non-fatal)
All five studies (3263 participants) reported the number of pa-
tients suffering from serious, but non-fatal, adverse events during
the study period, for which there was no statistically significant
difference (OR 1.09; 95% CI 0.76 to 1.55). However, the con-
fidence interval was wide. Data for Vogelmeier 2008 were kindly
supplied on request. It appears that Tashkin 2009 and Vogelmeier
2008 included COPD primary outcome data in the serious ad-
verse events but Aaron 2007 did not.
Secondary outcome: withdrawal
All five studies (3263 participants) reported the number of with-
drawals from study medication in each treatment group. Most of
the studies had relatively even withdrawal rates and there was no
statistically significant difference between the treatment groups
(OR 1.00; 95% CI 0.74 to 1.37). The exception was Tashkin
2009 (LABA + tiotropium 12%, tiotropium alone 6%), which in-
troduced moderate heterogeneity in the pooled result (I2 = 38%).
LABA plus tiotropium versus LABA
Vogelmeier 2008 was the only eligible study identified that com-
pared LABA + tiotropium versus LABA (417 patients). The study
was not blinded for this comparison for any of the outcomes
as tiotropium was administered open-label. The LABA used in
Vogelmeier 2008 was formoterol. The study reported the follow-
ing results for outcomes of interest for this review.
Primary outcomes
For the primary outcomes there were no significant differences be-
tween the treatments for quality of life (SGRQ,MD0.00; 95%CI
-2.70 to 2.70) and the number of patients admitted to hospital for
any cause (OR 1.02; 95% CI 0.37 to 2.76) (data kindly supplied
by Vogelmeier 2008). There were, however, fewer patients admit-
ted to hospital for an exacerbation in the formoterol + tiotropium
group (3 people out of 207) compared to the formoterol group
(9 people out of 221), but the number of events was low and the
confidence intervals were wide (OR 0.35; 95% CI 0.09 to 1.30).
There were no deaths reported in either of the treatment groups.
Secondary outcomes
For all of the secondary outcomes, there were wide confidence
intervals and no statistically significant difference between for-
moterol + tiotropium and formoterol alone: number of patients
suffering exacerbations (OR 0.76; 95% CI 0.36 to 1.61), lung
function (pre-dose FEV1 at the end of study, MD 0.00 L; 95%
CI -0.10 to 0.10), total symptom score (MD 0.09; 95% CI -0.46
to 0.64) (data kindly supplied by Vogelmeier 2008), number of
patients suffering serious non-fatal adverse events (OR 1.07; 95%
CI 0.44 to 2.63) (data kindly supplied by Vogelmeier 2008), and
withdrawals (OR 1.02; 95% CI 0.56 to 1.84).
D I S C U S S I O N
Summary of main results
This systematic review set out to investigate the long-term (three
months or longer) effects of tiotropium in combination with
LABA compared to either LABA alone or tiotropium alone, for
the treatment of COPD. Five randomised, parallel group, placebo-
controlled trials with 3473 participants were identified. All five
studied the effects of tiotropium in combination with LABA com-
pared to tiotropium alone, whereas only one of these studies
(Vogelmeier 2008, 417 participants) also looked at tiotropium in
combination with LABA compared to LABA alone.
LABA plus tiotropium versus tiotropium
This review found that compared to tiotropium alone, treat-
ment with tiotropium plus long-acting beta2-agonist resulted in
a slightly larger improvement in the mean health-related quality
of life (SGRQ, MD -1.61; 95% CI -2.93 to -0.29). This rep-
resented a change from baseline of -6.1 units with both treat-
ments compared to tiotropium alone, which improved by -4.5
units from baseline. This mean improvement was small in rela-
tion to the threshold of four units for a clinically significant differ-
ence. No significant differences were found in the other primary
outcomes (hospital admissions and mortality). Pre-bronchodila-
tor FEV1 also showed a statistically significant improvement with
LABA + tiotropium compared to tiotropium alone. None of the
other secondary outcomes (exacerbations, symptom scores, seri-
ous adverse events, and withdrawals) showed any statistically sig-
nificant difference between the groups. There were, however, wide
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confidence intervals regarding the results for all outcomes and
moderate heterogeneity for both exacerbations and withdrawals.
LABA plus tiotropium versus LABA
The study looking at the effect of formoterol + tiotropium ver-
sus formoterol (Vogelmeier 2008, 417 participants) showed very
wide confidence intervals and no statistically significant difference
between the treatment groups for any of the relevant outcomes
reported: health-related quality of life, hospitalisations (all-cause
and due to exacerbations), mortality (there were no deaths during
the study period in either group), exacerbations, FEV1, symptom
scores, serious adverse events or withdrawals. The fact that only
one study, with a relatively small total number of participants, was
included in this review makes the result for outcomes with few
events or small differences less reliable.
Overall completeness and applicability of
evidence
The lack of clear differences in effect between the treatment groups
for many of the outcomes may be due to the relatively short treat-
ment duration, with four out of five studies being shorter than
one year. This led to few events, wide confidence intervals and low
power to detect any differences. For continuous outcomes such
as lung function, quality of life and symptom scores, studies with
a duration of less than six months may not provide enough time
to reach a steady state, which may also influence the result in a
conservative way.
The results from this review indicate a small improvement in
the mean health-related quality of life and lung function for pa-
tients on a combination of LABA and tiotropium compared to
tiotropium alone. The mean improvement for both outcomes was
statistically significant but relatively small in relation to the mini-
mum clinically important difference for each outcome. However,
there may still be a significant number of patients who have a
clinically relevant improvement compared to the number with a
clinically relevant deterioration. This kind of responder analysis
may be a useful additional way of measuring health-related quality
of life.
Quality of the evidence
We encountered heterogeneity in the outcomes COPD exacer-
bations and the number of patients withdrawing from the stud-
ies. This could be from one or more of several sources, such as
the differences in definition of exacerbation and the length of the
studies. The smallest study (Tashkin 2009, 255 participants) had
more uneven withdrawal rates compared with the other studies.
Agreements and disagreements with other
studies or reviews
In addition to the long-term (three months or longer dura-
tion) studies presented in this review there have been several
studies looking at acute and short-term (up to six weeks) ef-
fects of tiotropium + LABA compared to tiotropium or LABA
alone (Cazzola 2010). One short-term, parallel group study also
looked at health-related quality of life using the SGRQ (Tashkin
2008a). After six weeks treatment they found no difference be-
tween tiotropium + LABA compared to tiotropium alone. How-
ever, at least for LABA it may take up to six months of treatment
to reach a steady state and to see the full effect on quality of life
(Calverley 2007).
Cost effectiveness
The cost effectiveness of tiotropium + LABA treatment compared
to both tiotropium alone and triple therapy consisting of ICS
and LABA combination inhaler + tiotropium has been assessed
for the Aaron 2007 study (Najafzadeh 2008). The setting for this
one-year study was within the Canadian healthcare system and
the cost effectiveness evaluation was based on 2006 prices. In
this study, treatment with tiotropium + LABA resulted in both
higher costs and a higher rate of exacerbations than treatment with
tiotropium alone. However, when focusing on patients with severe
COPD tiotropium + LABA resulted in equal exacerbation rates
and slightly lower costs compared to tiotropium alone, although
there was considerable uncertainty around this result. Therefore,
based on Aaron 2007, tiotropium on its own is the most cost ef-
fective treatment compared to tiotropium + LABA when looking
at the incremental cost for exacerbations avoided and per addi-
tional quality adjusted life year. However, for a chronic illness like
COPD a cost effectiveness study of one year is unlikely to capture
all relevant costs and benefits.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results from this review indicate a small mean improvement
in health-related quality of life for patients on a combination of
tiotropium and long-acting beta2-agonist compared to tiotropium
alone, but it is not clear how clinically important this mean
difference may be. Hospital admission and mortality have not
been shown to be altered by adding long-acting beta2-agonists to
tiotropium. There were not enough data to determine the relative
efficacy and safety of tiotropium plus long-acting beta2-agonist
compared to long-acting beta2-agonist alone. There were insuffi-
cient data to make comparisons between the different long-acting
beta2-agonists when used in addition to tiotropium.
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Implications for research
Additional long-term (12 months or longer) larger studies are
needed to clarify the risks and benefits of tiotropium + LABA
treatment compared to the individual drugs. If the number of
participants is large enough this will enable analysis to assess the
suitability of this combination of therapies for patients with dif-
ferent severities of COPD. For quality of life measurements in
future studies, it may be beneficial to use both mean changes with
95% confidence intervals and responders analysis. However, the
responders analysis would preferably include both the number of
people who have a clinically meaningful improvement as well as
the number of people who have a clinically meaningful worsen-
ing. Presenting just one side of the data distribution, as in the
percentage of patients with a clinically meaningful improvement,
is becoming more common but is of limited value.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aaron 2007
Methods Design: A randomised, double-blind, placebo-controlled, parallel group trial from Oc-
tober 2003 to January 2006. The trial included 27 Canadian medical centres; 20 centres
were academic hospital-based pulmonary clinics, 5 were community-based pulmonary
clinics, and 2 were community-based primary care clinics
Participants Population: 304 adults, with a clinical history of moderate or severe COPD as defined
by ATS and GOLD guidelines, were randomised to tiotropium + salmeterol (148) and
tiotropium (156)
Baseline Characteristics: Mean age 68 years. COPD severity moderate to severe with
mean FEV1 predicted of 38%. 57% men.
Inclusion Criteria: At least 1 exacerbation of COPD that required treatment with sys-
temic steroids or antibiotics within the 12 months before randomisation; age older than
35 years; a history of 10 pack-years or more of cigarette smoking; documented chronic
airflow obstruction, with an FEV1/FVC ratio less than 0.70 and a post-bronchodilator
FEV1 less than 65% of the predicted value.
Exclusion Criteria: History of physician-diagnosed asthma before 40 years of age; his-
tory of physician-diagnosed chronic congestive heart failure with known persistent severe
left ventricular dysfunction; those receiving oral prednisone; those with a known hy-
persensitivity or intolerance to tiotropium, salmeterol, or fluticasone-salmeterol; history
of severe glaucoma or severe urinary tract obstruction, previous lung transplantation or
lung volume reduction surgery, or diffuse bilateral bronchiectasis; and those who were
pregnant or were breastfeeding
Interventions 1. Tiotropium + salmeterol: tiotropium 18 µg once daily using a Handihaler plus sal-
meterol 25 µg/puff, 2 puffs twice daily using a pressurized metered-dose inhaler using a
spacer device
2. Tiotropium + placebo: tiotropium, 18 µg once daily, plus placebo inhaler, 2 puffs
twice daily
Outcomes Primary: Proportion of patients with one or more exacerbation of COPD
Secondary: Mean number of COPD exacerbations per patient-year; the total number of
exacerbations that resulted in urgent visits to a health care provider or emergency depart-
ment; the number of hospitalizations for COPD; the total number of hospitalizations
for all causes; changes in health-related quality of life, dyspnoea, lung function
Notes Co-medication: All study patients were provided with inhaled albuterol and were in-
structed to use it when necessary to relieve symptoms. Any treatment with inhaled cor-
ticosteroids, long-acting 2-agonists, and anticholinergics that the patient may have been
using before entry was discontinued on entry into the study. Therapy with other respira-
tory medications, such as oxygen, antileukotrienes, and methylxanthines, was continued
in all patient groups
Risk of bias
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Aaron 2007 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done through central
allocation of a randomisation schedule that
was prepared from a computer-generated
random listing of the 3 treatment alloca-
tions, blocked in variable blocks of 9 or 12
and stratified by site
Allocation concealment (selection bias) Unclear risk Neither research staff nor patients were
aware of the treatment assignment before
or after randomisation
Blinding of participants and personnel
(LABA+TIO versus TIO) (performance
bias)
Low risk Neither research staff nor patients were
aware of the treatment assignment be-
fore or after randomisation. The metered-
dose inhalers containing placebo, salme-
terol, and fluticasone-salmeterol were iden-
tical in taste and appearance, and they
were enclosed in identical tamper-proof
blinding devices. The medication canisters
within the blinding devices were stripped
of any identifying labelling
Blinding of outcome assessment (detection
bias)
Exacerbations
Low risk The assembled data from the visit for the
suspected exacerbation were presented to a
blinded adjudication committee for review,
and the committee confirmed whether
the encounter met the study definition of
COPD exacerbation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The number of people who stopped drug
therapy was high in both groups. 74 pa-
tients (47%)withdrew from the tiotropium
+ placebo group and 64 patients (43%)
on LABA + tiotropium group. However,
the number of people who did not com-
plete the trial was lower (30 patients (19%)
on tiotropium + placebo and 20 patients
(14%) on LABA + tiotropium). The in-
complete data were however addressed by
sensitivity analyses of the data comprising
alternative assumptions for patients who
prematurely withdrew from treatment
Selective reporting (reporting bias) Low risk Results for all listed primary and secondary
outcomes were reported
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Mahler 2010a
Methods Design: Amulti-centre, multi-national, randomised, double-blind, parallel-group study
fromMarch 2009 to March 2010. The trial included 186 study centres in 14 countries:
Argentina (10), Australia (6), Colombia (5), Denmark (5), Germany (25), Greece (4)
, Guatemala (5), Mexico (5), Peru (6), Philippines (2), South Africa (6), Spain (13),
Turkey (13), and USA (81)
Participants Population: 1134 patients with a clinical history of moderate or severe COPD as defined
byGOLDguidelines, were randomised to tiotropium+ indacaterol (570) and tiotropium
(564)
Baseline Characteristics: Mean age 64 years, 67%male, mean FEV1 1.3 L, mean FEV1
predicted 49%, 47 pack-years smoking history.
Inclusion Criteria: Men and women aged ≥40 years with moderate-to-severe COPD,
with a smoking history ≥10 pack-years and post-bronchodilator FEV1 ≤ 65% and ≥
30% predicted and FEV1/FVC < 70%.
Exclusion Criteria: Patients who have received systematic corticosteroids and/or antibi-
otics and/or was hospitalised for a COPD exacerbation in the 6 weeks prior to screening
or during the run-in period or had a respiratory tract infection within 6 weeks prior to
screening. Patients with concomitant pulmonary disease, a history of asthma, diabetes
Type I or uncontrolled diabetes Type II, lung cancer or a history of lung cancer, a history
of certain cardiovascular comorbid conditions
Interventions 1. Indacaterol 150 µg through single-dose dry powder inhaler (SDDPI), once daily +
tiotropium 18 µg through SDDPI Handihaler, once daily
2. Placebo to indacaterol + tiotropium 18 µg through SDDPI Handihaler, once daily
Outcomes Primary: Standardised area under the curve (AUC) FEV1 between 5min and 8h post-
dose after 12 weeks of treatment.
Secondary: Trough FEV1 on day 1 and after 12 weeks treatment, FEV1 AUC (5min-
8h) day 1, FEV1 AUC (5min-4h) on day 1 and after 12 weeks of treatment, resting
inspiratory capacity (IC), use of albuterol as rescue medication, safety (adverse events
and serious adverse events)
Notes Co-medication: Albuterol was available for rescue use. Patients receiving inhaled corti-
costeroids (ICS) at baseline continued treatment (or the ICS component alone if taken as
a fixed combination with a bronchodilator) at equivalent dose and regimen throughout
the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A patient randomisation list was produced
by the IVRS provider using a validated sys-
tem that automates the random assignment
of patient numbers to randomisation num-
bers
Allocation concealment (selection bias) Low risk The randomisation numbers were linked
to the different treatment arms, which in
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Mahler 2010a (Continued)
turn were linked tomedication numbers. A
separate medication randomisation list was
produced by or under the responsibility of
Novartis Drug Supply Management using
a validated system that automates the ran-
dom assignment of medication numbers to
medication packs containing each of the
study drugs
Blinding of participants and personnel
(LABA+TIO versus TIO) (performance
bias)
Low risk Patients, investigator staff, persons per-
forming the assessments, data analysts and
the Novartis trial team were all blinded
Blinding of outcome assessment (detection
bias)
Exacerbations
Low risk Persons performing the assessments were
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk The withdrawal rates were low and
even (tiotropium + indacaterol 6.8%,
tiotropium 6.2%)
Selective reporting (reporting bias) Low risk Results for all listed primary and secondary
outcomes were reported
Mahler 2010b
Methods Design: Amulti-centre, multi-national, randomised, double-blind, parallel-group study
from April 2009 to February 2010. The trial included 182 study centres in 11 countries:
Argentina (9), Canada (16), Colombia (3), Czech Republic (9), Hungary (4), India (9)
, Netherlands (6), Philippines (3), Slovakia (10), Spain (11), and USA (102)
Participants Population: 1142 patients with a clinical history of moderate or severe COPD as defined
byGOLDguidelines, were randomised to tiotropium+ indacaterol (572) and tiotropium
(570)
Baseline Characteristics: Mean age 63 years, 65%male, mean FEV1 1.3 L, mean FEV1
predicted 49%, 46 pack-years smoking history.
Inclusion Criteria: Men and women aged ≥40 years with moderate-to-severe COPD,
with a smoking history ≥10 pack-years and post-bronchodilator FEV1 ≤ 65% and ≥
30% predicted and FEV1/FVC < 70%.
Exclusion Criteria: Patients who have received systematic corticosteroids and/or antibi-
otics and/or was hospitalised for a COPD exacerbation in the 6 weeks prior to screening
or during the run-in period or had a respiratory tract infection within 6 weeks prior to
screening. Patients with concomitant pulmonary disease, a history of asthma, diabetes
Type I or uncontrolled diabetes Type II, lung cancer or a history of lung cancer, a history
of certain cardiovascular comorbid conditions
Interventions 1. Indacaterol 150 µg through single-dose dry powder inhaler (SDDPI), once daily +
tiotropium 18 µg through SDDPI Handihaler, once daily
2. Placebo to indacaterol + tiotropium 18 µg through SDDPI Handihaler, once daily
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Mahler 2010b (Continued)
Outcomes Primary: Standardised area under the curve (AUC) FEV1 between 5min and 8h post-
dose after 12 weeks of treatment.
Secondary: Trough FEV1 on day 1 and after 12 weeks treatment, FEV1 AUC (5min-
8h) day 1, FEV1 AUC (5min-4h) on day 1 and after 12 weeks of treatment, resting
inspiratory capacity (IC), use of albuterol as rescue medication, safety (adverse events
and serious adverse events)
Notes Co-medication: Albuterol was available for rescue use. Patients receiving inhaled corti-
costeroids (ICS) at baseline continued treatment (or the ICS component alone if taken as
a fixed combination with a bronchodilator) at equivalent dose and regimen throughout
the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A patient randomisation list was produced
by the IVRS provider using a validated sys-
tem that automates the random assignment
of patient numbers to randomisation num-
bers
Allocation concealment (selection bias) Low risk The randomisation numbers were linked
to the different treatment arms, which in
turn were linked tomedication numbers. A
separate medication randomisation list was
produced by or under the responsibility of
Novartis Drug Supply Management using
a validated system that automates the ran-
dom assignment of medication numbers to
medication packs containing each of the
study drugs
Blinding of participants and personnel
(LABA+TIO versus TIO) (performance
bias)
Low risk Patients, investigator staff, persons per-
forming the assessments, data analysts and
the Novartis trial team were all blinded
Blinding of outcome assessment (detection
bias)
Exacerbations
Low risk Persons performing the assessments were
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk The withdrawal rates were low and
even (tiotropium + indacaterol 5.1%,
tiotropium 6.5%)
Selective reporting (reporting bias) Low risk Results for all listed primary and secondary
outcomes were reported
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Tashkin 2009
Methods Design: A randomised, double-blind, active-control, parallel group trial. The trial in-
cluded 35 centres across the United States, of which the majority were primary care
centres
Participants Population: 255 adults with a clinical history of COPD were randomised to tiotropium
+ formoterol (124) and tiotropium (131)
Baseline Characteristics: Mean age 64 years. COPD severity mild to severe. 67% men.
Inclusion Criteria: Male and non-pregnant female patients aged >40 years who had
a clinical history of COPD were enrolled in this study. Each patient had a post-bron-
chodilator FEV1 < 70% and >30% predicted normal or >0.75 L, whichever was less,
at run-in, and a FEV1 to FVC ratio (FEV1/FVC) of < 0.70 at screening and run-in.
Daytime and/or nighttime symptoms of COPD, including dyspnoea, must have been
present on ≥4 of the 7 days before the baseline visit
Exclusion Criteria: A current or previous history of asthma or other significant medical
condition that may have interfered with study treatment as assessed by the investigator,
smoking cessation within the previous 3 months, ventilator support for respiratory fail-
ure within the previous year, the use of oxygen (≥2 L/min or for >2 h/d), initiation of
pulmonary rehabilitation within the previous 3 months, the requirement for nasal con-
tinuous positive airway pressure or bilevel positive airway pressure, clinically significant
lung disease other than COPD (i.e., bronchiectasis, sarcoidosis, pulmonary fibrosis, tu-
berculosis), sleep apnoea, chronic narrow-angle glaucoma, symptomatic prostatic hyper-
plasia or bladder neck obstruction, and the need for chronic or prophylactic antibiotic
therapy
Interventions 1. Formoterol (Foradil Aerolizer) 12 µg twice daily and tiotropium (Handihaler) 18 µg
once-daily in the morning delivered via 2 separate inhalers
2. Formoterol-matched placebo twice-daily and tiotropium 18 µg once-daily delivered
via 2 separate inhalers
Outcomes Primary: The normalized area under the curve (AUC) for FEV1 measured 0 to 4 hours
post-morning dose (FEV1 AUC0-4h) at the last visit.
Secondary: Changes from baseline in trough (average of values obtained 10 and 30 min
pre-dose) FEV1 and FVC, weekly morning and evening peak expiratory flow (PEF),
symptom severity scores, transition dyspnoea index (TDI), and health related quality
of life (St. George’s Respiratory Questionnaire, SGRQ) scores, number and severity of
exacerbations, the global therapeutic response, discontinuations because of worsening
COPD, and percentages of patients achieving targeted improvements in the SGRQ and
TDI scores, use of rescue albuterol, nocturnal awakenings requiring rescue albuterol,
changes in study or concomitant medications, and adverse events
Notes Co-medication: Continued use of prior stable inhaled corticosteroid regimens and sys-
temic corticosteroids for the treatment of exacerbations was permitted throughout the
study. All patients were provided with albuterol for use as rescue medication
Run-in: Following screening, prohibited medications (i.e., beta-agonists, beta-blockers,
cromolyn sodium, ipratropium bromide, leukotriene antagonists, cytotoxic agent, and
theophylline) were withdrawn. Patients previously using TIO or FORM discontinued
the drugs at least 4 weeks or 48 hours before screening, respectively. Patients completed
a 2-week run-in period using placebo and as-needed rescue albuterol
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Tashkin 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised sequentially as
they qualified for the study according to
a pre-generated computer code labelled on
the medication kit
Allocation concealment (selection bias) Unclear risk A pre-generated computer code was la-
belled on the medication kit
Blinding of participants and personnel
(LABA+TIO versus TIO) (performance
bias)
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
Exacerbations
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The number of withdrawals in the dif-
ferent groups was relatively low but un-
even (LABA + tiotropium (14.5%), and
tiotropium + placebo (6.1%))
Selective reporting (reporting bias) Low risk Results for all listed primary and secondary
outcomes were reported
Vogelmeier 2008
Methods Design: A randomised, partly-blind , partly placebo-controlled, parallel group trial from
October 2004 to November 2005. The trial included
86 centres in Germany (30), Italy (19), Netherlands (9), Russian federation (9), Poland
(7), Czech Republic (4), Spain (4) and Hungary (4)
Participants Population: 638 adults, with a clinical history of moderate to very severe COPD as
defined by GOLD guidelines, were randomised to tiotropium + formoterol (207), for-
moterol (210), and tiotropium (221)
Baseline Characteristics: Mean age 63 years. COPD severity moderate to very severe
with mean FEV1 predicted of 52%. 78% men.
Inclusion Criteria: Males and females with stable COPD aged ≥40 years at COPD
onset and with a smoking history of ≥10 pack-years, forced expiratory volume in 1
second (FEV1) < 70% of patient’s predicted normal value (and ≥1.00 L), and FEV1/
forced vital capacity (FVC) < 70%. They were to be symptomatic on at least 4 of 7 days
prior to randomisation (symptom score >0 on diary card)
Exclusion Criteria: Patients who had a respiratory tract infection or had been hospi-
talised for an acute exacerbation of COPD within the month prior to screening. Patients
with a clinically significant condition such as ischaemic heart disease that might com-
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Vogelmeier 2008 (Continued)
promise patient safety or compliance were also excluded
Interventions 1. Formoterol 10 µg twice daily via multi-dose dry powder inhaler (MDDPI)
2. Tiotropium 18 µg once daily via the HandiHaler + formoterol 10 µg via MDDPI
Outcomes Primary: FEV1 measured 2 hours post-dose after 24 weeks of treatment.
Secondary: FEV1 and FVC at other time points during the study (5 min, 2 and 3 hours
post-dose following the first dose of treatment, and after 12 and 24 weeks of treatment)
; COPD exacerbations; symptom scores, rescue medication use and PEF; quality of life,
and 6-minute walking distance
Notes Co-medication: Salbutamol pMDI (2 × 100 µg/puff ) was permitted as rescue medica-
tion. Patients were asked not to use salbutamol in the 8 hours before a study visit. Patients
could receive inhaled corticosteroids (ICS) at a stable daily dose (any patients receiving
fixed combinations of ICS and beta2-agonists were switched to receive the same dose of
ICS and on demand salbutamol)
Run-in: A screening period of up to 4 weeks included 2 weeks for washout of disallowed
medications and 2 weeks for eligibility assessment and baseline evaluations
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomisation list was produced using
a validated system that automates the ran-
dom assignment of treatment groups to
randomisation numbers in the specified
ratio. The randomisation scheme was re-
viewed by a Biostatistics Quality Assurance
Group and locked by them after approval
Allocation concealment (selection bias) Low risk Randomisation data were kept strictly con-
fidential until the time of unblinding, and
was not accessible by anyone else involved
in the study
Blinding of participants and personnel
(LABA+TIO versus TIO) (performance
bias)
Low risk The study was partially blinded. The study
was double-blind for treatment compari-
son tiotropium + formoterol vs. tiotropium
+placebo (MDDPI only), but not for other
comparisons as tiotropium was adminis-
tered open-label. Randomisation was not
stratified. Certihaler active and placebo de-
vices were identical in packaging, labelling,
schedule of administration and appearance
Blinding of participants and personnel
(LABA+TIO versus LABA) (performance
bias)
High risk The study was partially blinded. The study
was double-blind for treatment compari-
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Vogelmeier 2008 (Continued)
son tiotropium + formoterol vs. tiotropium
+placebo (MDDPI only), but not for other
comparisons as tiotropium was adminis-
tered open-label. Randomisation was not
stratified. Certihaler active and placebo de-
vices were identical in packaging, labelling,
schedule of administration and appearance
Blinding of outcome assessment (detection
bias)
Exacerbations
Low risk Persons performing the assessments, and
data analysts were blinded to the identity
of the treatment from the time of randomi-
sation until database lock
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of withdrawals in the different
groups were relatively low and even (LABA
+ tiotropium (12.1%), formoterol (11.9%)
and tiotropium + placebo (13.1%))
Selective reporting (reporting bias) Low risk Results for all listed primary and secondary
outcomes were reported
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bateman 2001 No tiotropium plus long-acting beta2-agonists combination treatment
Brusasco 2003 No tiotropium plus long-acting beta2-agonists combination treatment
Di Marco 2003 No tiotropium plus long-acting beta2-agonists combination treatment
Fujimoto 2007 8 weeks of treatment and no tiotropium plus long-acting beta2-agonists combination treatment
Gross 2003 4 weeks of treatment, no tiotropium plus long-acting beta2-agonists combination treatment, and crossover design
Jones 2010 crossover design
Meyer 2008 2 weeks of treatment, no tiotropium plus long-acting beta2-agonists combination treatment, and crossover design
New 2009 6 weeks of treatment
ten Hacken 2007 6 weeks of treatment, no tiotropium plus long-acting beta2-agonists combination treatment, and crossover design
van Noord 2003 6 weeks of treatment and crossover design
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van Noord 2005 6 weeks of treatment and crossover design
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D A T A A N D A N A L Y S E S
Comparison 1. LABA plus tiotropium versus tiotropium
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in quality of life 2 732 Mean Difference (Fixed, 95% CI) -1.61 [-2.93, -0.29]
1.1 Salmeterol 1 304 Mean Difference (Fixed, 95% CI) -1.8 [-3.32, -0.28]
1.2 Formoterol 1 428 Mean Difference (Fixed, 95% CI) -1.0 [-3.70, 1.70]
2 Hospital admission (all cause) 2 732 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.63, 1.61]
2.1 Salmeterol 1 304 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.61, 1.76]
2.2 Formoterol 1 428 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.36, 2.50]
3 Hospital admission
(exacerbation)
2 732 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.63, 1.81]
3.1 Salmeterol 1 304 Odds Ratio (M-H, Fixed, 95% CI) 1.16 [0.66, 2.06]
3.2 Formoterol 1 428 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.15, 2.69]
4 Mortality (all cause) 5 3263 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.56 [0.56, 4.33]
4.1 Salmeterol 1 304 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.59 [0.45, 5.62]
4.2 Formoterol 2 683 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Indacaterol 2 2276 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.48 [0.26, 8.57]
5 Exacerbation 3 Odds Ratio (M-H, Random, 95% CI) Totals not selected
5.1 Salmeterol 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Formoterol 2 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Trough FEV1 5 3263 Mean Difference (Fixed, 95% CI) 0.07 [0.05, 0.09]
6.1 Salmeterol 1 304 Mean Difference (Fixed, 95% CI) 0.03 [-0.07, 0.13]
6.2 Formoterol 2 683 Mean Difference (Fixed, 95% CI) 0.06 [0.02, 0.11]
6.3 Indacaterol 2 2276 Mean Difference (Fixed, 95% CI) 0.07 [0.05, 0.10]
7 Symptom score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Formoterol 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Serious adverse event (non-fatal) 5 3263 Odds Ratio (M-H, Fixed, 95% CI) 1.09 [0.76, 1.55]
8.1 Salmeterol 1 304 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.37, 2.40]
8.2 Formoterol 2 683 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.54, 2.13]
8.3 Indacaterol 2 2276 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.72, 1.81]
9 Withdrawal 5 3263 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.74, 1.37]
9.1 Salmeterol 1 304 Odds Ratio (M-H, Random, 95% CI) 0.84 [0.54, 1.33]
9.2 Formoterol 2 683 Odds Ratio (M-H, Random, 95% CI) 1.46 [0.52, 4.09]
9.3 Indacaterol 2 2276 Odds Ratio (M-H, Random, 95% CI) 0.93 [0.65, 1.34]
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Analysis 1.1. Comparison 1 LABA plus tiotropium versus tiotropium, Outcome 1 Change in quality of life.
Review: Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease
Comparison: 1 LABA plus tiotropium versus tiotropium
Outcome: 1 Change in quality of life
Study or subgroup LABA + tiotropium tiotropium Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Salmeterol
Aaron 2007 148 156 -1.8 (0.774) 76.0 % -1.80 [ -3.32, -0.28 ]
Subtotal (95% CI) 76.0 % -1.80 [ -3.32, -0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.33 (P = 0.020)
2 Formoterol
Vogelmeier 2008 207 221 -1 (1.378) 24.0 % -1.00 [ -3.70, 1.70 ]
Subtotal (95% CI) 24.0 % -1.00 [ -3.70, 1.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Total (95% CI) 100.0 % -1.61 [ -2.93, -0.29 ]
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 2.38 (P = 0.017)
Test for subgroup differences: Chi2 = 0.26, df = 1 (P = 0.61), I2 =0.0%
-4 -2 0 2 4
Favours LABA + tiotropium Favours tiotropium
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Analysis 1.2. Comparison 1 LABA plus tiotropium versus tiotropium, Outcome 2 Hospital admission (all
cause).
Review: Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease
Comparison: 1 LABA plus tiotropium versus tiotropium
Outcome: 2 Hospital admission (all cause)
Study or subgroup LABA + tiotropium tiotropium Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Salmeterol
Aaron 2007 35/148 36/156 76.2 % 1.03 [ 0.61, 1.76 ]
Subtotal (95% CI) 148 156 76.2 % 1.03 [ 0.61, 1.76 ]
Total events: 35 (LABA + tiotropium), 36 (tiotropium)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
2 Formoterol
Vogelmeier 2008 8/207 9/221 23.8 % 0.95 [ 0.36, 2.50 ]
Subtotal (95% CI) 207 221 23.8 % 0.95 [ 0.36, 2.50 ]
Total events: 8 (LABA + tiotropium), 9 (tiotropium)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Total (95% CI) 355 377 100.0 % 1.01 [ 0.63, 1.61 ]
Total events: 43 (LABA + tiotropium), 45 (tiotropium)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
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Analysis 1.3. Comparison 1 LABA plus tiotropium versus tiotropium, Outcome 3 Hospital admission
(exacerbation).
Review: Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease
Comparison: 1 LABA plus tiotropium versus tiotropium
Outcome: 3 Hospital admission (exacerbation)
Study or subgroup LABA + tiotropium tiotropium Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Salmeterol
Aaron 2007 30/148 28/156 82.0 % 1.16 [ 0.66, 2.06 ]
Subtotal (95% CI) 148 156 82.0 % 1.16 [ 0.66, 2.06 ]
Total events: 30 (LABA + tiotropium), 28 (tiotropium)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
2 Formoterol
Vogelmeier 2008 3/207 5/221 18.0 % 0.64 [ 0.15, 2.69 ]
Subtotal (95% CI) 207 221 18.0 % 0.64 [ 0.15, 2.69 ]
Total events: 3 (LABA + tiotropium), 5 (tiotropium)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Total (95% CI) 355 377 100.0 % 1.07 [ 0.63, 1.81 ]
Total events: 33 (LABA + tiotropium), 33 (tiotropium)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 0.58, df = 1 (P = 0.45), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours LABA + tiotropium Favours tiotropium
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Analysis 1.4. Comparison 1 LABA plus tiotropium versus tiotropium, Outcome 4 Mortality (all cause).
Review: Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease
Comparison: 1 LABA plus tiotropium versus tiotropium
Outcome: 4 Mortality (all cause)
Study or subgroup LABA + tiotropium tiotropium
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Salmeterol
Aaron 2007 6/148 4/156 1.59 [ 0.45, 5.62 ]
Subtotal (95% CI) 148 156 1.59 [ 0.45, 5.62 ]
Total events: 6 (LABA + tiotropium), 4 (tiotropium)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
2 Formoterol
Tashkin 2009 0/124 0/131 0.0 [ 0.0, 0.0 ]
Vogelmeier 2008 0/207 0/221 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 331 352 0.0 [ 0.0, 0.0 ]
Total events: 0 (LABA + tiotropium), 0 (tiotropium)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
3 Indacaterol
Mahler 2010a 2/570 0/564 7.32 [ 0.46, 117.25 ]
Mahler 2010b 1/572 2/570 0.51 [ 0.05, 4.92 ]
Subtotal (95% CI) 1142 1134 1.48 [ 0.26, 8.57 ]
Total events: 3 (LABA + tiotropium), 2 (tiotropium)
Heterogeneity: Chi2 = 2.12, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 1621 1642 1.56 [ 0.56, 4.33 ]
Total events: 9 (LABA + tiotropium), 6 (tiotropium)
Heterogeneity: Chi2 = 2.13, df = 2 (P = 0.34); I2 =6%
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
0.005 0.1 1 10 200
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Analysis 1.5. Comparison 1 LABA plus tiotropium versus tiotropium, Outcome 5 Exacerbation.
Review: Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease
Comparison: 1 LABA plus tiotropium versus tiotropium
Outcome: 5 Exacerbation
Study or subgroup
Favours
LABA +
tiotropium tiotropium Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Salmeterol
Aaron 2007 96/148 98/156 1.09 [ 0.68, 1.75 ]
2 Formoterol
Tashkin 2009 21/124 14/131 1.70 [ 0.82, 3.52 ]
Vogelmeier 2008 13/207 23/221 0.58 [ 0.28, 1.17 ]
0.1 0.2 0.5 1 2 5 10
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Analysis 1.6. Comparison 1 LABA plus tiotropium versus tiotropium, Outcome 6 Trough FEV1.
Review: Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease
Comparison: 1 LABA plus tiotropium versus tiotropium
Outcome: 6 Trough FEV1
Study or subgroup LABA + tiotropium LABA Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Salmeterol
Aaron 2007 148 156 0.03 (0.051) 4.2 % 0.03 [ -0.07, 0.13 ]
Subtotal (95% CI) 4.2 % 0.03 [ -0.07, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
2 Formoterol
Tashkin 2009 124 131 0.09 (0.028) 14.1 % 0.09 [ 0.04, 0.14 ]
Vogelmeier 2008 207 221 -0.01 (0.046) 5.2 % -0.01 [ -0.10, 0.08 ]
Subtotal (95% CI) 19.3 % 0.06 [ 0.02, 0.11 ]
Heterogeneity: Chi2 = 3.45, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 2.63 (P = 0.0085)
3 Indacaterol
Mahler 2010a 570 564 0.08 (0.02) 27.5 % 0.08 [ 0.04, 0.12 ]
Mahler 2010b 572 570 0.07 (0.015) 49.0 % 0.07 [ 0.04, 0.10 ]
Subtotal (95% CI) 76.5 % 0.07 [ 0.05, 0.10 ]
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 6.13 (P < 0.00001)
Total (95% CI) 100.0 % 0.07 [ 0.05, 0.09 ]
Heterogeneity: Chi2 = 4.40, df = 4 (P = 0.35); I2 =9%
Test for overall effect: Z = 6.64 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.79, df = 2 (P = 0.67), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
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Analysis 1.7. Comparison 1 LABA plus tiotropium versus tiotropium, Outcome 7 Symptom score.
Review: Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease
Comparison: 1 LABA plus tiotropium versus tiotropium
Outcome: 7 Symptom score
Study or subgroup LABA + tiotropium tiotropium
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Formoterol
Vogelmeier 2008 207 4.61 (2.81) 221 4.4 (2.59) 0.21 [ -0.30, 0.72 ]
-2 -1 0 1 2
Favours LABA + tiotropium Favours tiotropium
Analysis 1.8. Comparison 1 LABA plus tiotropium versus tiotropium, Outcome 8 Serious adverse event
(non-fatal).
Review: Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease
Comparison: 1 LABA plus tiotropium versus tiotropium
Outcome: 8 Serious adverse event (non-fatal)
Study or subgroup LABA + tiotropium tiotropium Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Salmeterol
Aaron 2007 9/148 10/156 15.6 % 0.95 [ 0.37, 2.40 ]
Subtotal (95% CI) 148 156 15.6 % 0.95 [ 0.37, 2.40 ]
Total events: 9 (LABA + tiotropium), 10 (tiotropium)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
2 Formoterol
Tashkin 2009 7/124 7/131 10.9 % 1.06 [ 0.36, 3.11 ]
Vogelmeier 2008 10/207 10/221 15.7 % 1.07 [ 0.44, 2.63 ]
Subtotal (95% CI) 331 352 26.6 % 1.07 [ 0.54, 2.13 ]
Total events: 17 (LABA + tiotropium), 17 (tiotropium)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.85)
0.1 0.2 0.5 1 2 5 10
Favours LABA + tiotropium Favours tiotropium
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Study or subgroup LABA + tiotropium tiotropium Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
3 Indacaterol
Mahler 2010a 21/570 17/564 28.1 % 1.23 [ 0.64, 2.36 ]
Mahler 2010b 19/572 18/570 29.7 % 1.05 [ 0.55, 2.03 ]
Subtotal (95% CI) 1142 1134 57.8 % 1.14 [ 0.72, 1.81 ]
Total events: 40 (LABA + tiotropium), 35 (tiotropium)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Total (95% CI) 1621 1642 100.0 % 1.09 [ 0.76, 1.55 ]
Total events: 66 (LABA + tiotropium), 62 (tiotropium)
Heterogeneity: Chi2 = 0.24, df = 4 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 0.13, df = 2 (P = 0.94), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours LABA + tiotropium Favours tiotropium
Analysis 1.9. Comparison 1 LABA plus tiotropium versus tiotropium, Outcome 9 Withdrawal.
Review: Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease
Comparison: 1 LABA plus tiotropium versus tiotropium
Outcome: 9 Withdrawal
Study or subgroup LABA + tiotropium tiotropium Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Salmeterol
Aaron 2007 64/148 74/156 24.9 % 0.84 [ 0.54, 1.33 ]
Subtotal (95% CI) 148 156 24.9 % 0.84 [ 0.54, 1.33 ]
Total events: 64 (LABA + tiotropium), 74 (tiotropium)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
2 Formoterol
Tashkin 2009 18/124 8/131 10.2 % 2.61 [ 1.09, 6.25 ]
Vogelmeier 2008 25/207 29/221 18.9 % 0.91 [ 0.51, 1.61 ]
Subtotal (95% CI) 331 352 29.1 % 1.46 [ 0.52, 4.09 ]
0.1 0.2 0.5 1 2 5 10
Favours LABA + tiotropium Favours tiotropium
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Study or subgroup LABA + tiotropium tiotropium Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 43 (LABA + tiotropium), 37 (tiotropium)
Heterogeneity: Tau2 = 0.42; Chi2 = 3.93, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.72 (P = 0.47)
3 Indacaterol
Mahler 2010a 39/570 35/564 23.8 % 1.11 [ 0.69, 1.78 ]
Mahler 2010b 29/572 37/570 22.2 % 0.77 [ 0.47, 1.27 ]
Subtotal (95% CI) 1142 1134 46.0 % 0.93 [ 0.65, 1.34 ]
Total events: 68 (LABA + tiotropium), 72 (tiotropium)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.09, df = 1 (P = 0.30); I2 =8%
Test for overall effect: Z = 0.38 (P = 0.71)
Total (95% CI) 1621 1642 100.0 % 1.00 [ 0.74, 1.37 ]
Total events: 175 (LABA + tiotropium), 183 (tiotropium)
Heterogeneity: Tau2 = 0.05; Chi2 = 6.50, df = 4 (P = 0.16); I2 =38%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Chi2 = 0.92, df = 2 (P = 0.63), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours LABA + tiotropium Favours tiotropium
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
CENTRAL (the Cochrane Library) Quarterly
PSYCHINFO (Ovid) Monthly
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CINAHL (Ebsco) Monthly
AMED (Ebsco) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
COPD search
1. Lung Diseases, Obstructive/
2. exp Pulmonary Disease, Chronic Obstructive/
3. emphysema$.mp.
4. (chronic$ adj3 bronchiti$).mp.
5. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).mp.
6. COPD.mp.
7. COAD.mp.
8. COBD.mp.
9. AECB.mp.
10. or/1-9
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Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases
Appendix 2. Search strategy for clinicaltrials.gov
COPD AND tiotropium AND salmeterol
COPD AND tiotropium AND formoterol
COPD AND tiotropium AND indacaterol
H I S T O R Y
Protocol first published: Issue 2, 2011
Review first published: Issue 4, 2012
C O N T R I B U T I O N S O F A U T H O R S
Charlotta Karner assessed studies for inclusion, extracted data, conducted the analysis and wrote the review with input from Chris
Cates.
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